| Field | Specification |
|---|---|
| Target | |
| Alternative names | Catenin delta-1; Cadherin-associated Src substrate; CAS; p120 catenin; p120(ctn); p120(cas); CTNND1; KIAA0384 |
| UniProt # | |
| Host | |
| Clone | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human delta 1 Catenin/CAS/CTNND1 recombinant protein (Position: H64-K930). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
Clone 8G7E4 is a mouse monoclonal antibody that recognizes catenin delta-1 (gene CTNND1) in human, mouse and rat samples and is validated for Western blot, IHC and ICC/IF. The predicted molecular weight is 108.2 kDa, and the supplier reports an observed band at about 100 kDa.
p120-catenin (CTNND1) binds the juxtamembrane region of classical cadherins such as E- and N-cadherin and prevents their endocytosis, keeping adherens junctions stable. It also regulates Rho family GTPases and the transcription factor Kaiso, and it is a substrate of SRC and several receptor tyrosine kinases. It is studied in epithelial adhesion, cell migration and cancer.
| Target | Catenin delta-1 (gene CTNND1; UniProt O60716, human) |
|---|---|
| Clone | 8G7E4 |
| Host / Clonality / Isotype | Mouse / Monoclonal / Mouse IgG2b |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 108.2 kDa |
| Observed MW | 100 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human, Mouse, Rat) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
Samples with a confirmed band (WB): human A549 cells, human Hacat cells, human RT4 cells, human T47D cells, rat PC-12 cells, rat C6 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:10000, ECL detection.
Samples with confirmed staining (IHC): human breast cancer tissue, human colorectal adenocarcinoma tissue, human laryngeal squamous cells carcinoma tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): RT4 cells.
Immunogen
Recombinant human delta 1 Catenin/CAS/CTNND1 fragment (His64–Lys930), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places catenin delta-1 in the cell junction, cytoplasm, nucleus and cell membrane. Tissue expression noted by UniProt (human): Expressed in vascular endothelium. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
